Get started
Work

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis

Year: 2020
Type: article
Study design: Observational Study
DOI: 10.1016/j.clml.2020.12.013
Authors: Stephen D. Smith, Paolo Lopedote, Yazeed Samara, Matthew Mei, Alex F. Herrera, Allison M. Winter, Brian T. Hill, Mazyar Shadman, Chaitra Ujjani, Ryan C. Lynch, Caron A. Jacobson, Austin I. Kim, Paolo Caimi, Filippo Milano, Ajay K. Gopal
Institutions: University of Washington, Fred Hutch Cancer Center, University of Bologna, City Of Hope National Medical Center, Cleveland Clinic, Dana-Farber Cancer Institute, Case Western Reserve University
Language: English
Field: Medicine
Open Access status: closed
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Bayer, Merck, Novartis, Roche, Gilead Sciences, Celgene, AbbVie, Karyopharm Therapeutics, Seattle Genetics, Portola Pharmaceuticals, TG Therapeutics, Sunesis, BeiGene, Incyte, Genentech, Merck Sharp and Dohme, Pharmacyclics, Juno Therapeutics, Janssen Biotech, Seattle Translational Tumor Research
OpenAlex ID: W3111739914
FWCI: 2.898
Cites: 18
Cited by: 25
Related to: 10